Related Experiment Videos
Retroperitoneal fibrosis. A true connective tissue disease
1Duke University Medical Center, Durham, North Carolina, USA.
Rheumatic Diseases Clinics of North America
|February 1, 1996
Summary
Retroperitoneal fibrosis is a rare condition causing ureteral obstruction and potential kidney issues. Prednisone and tamoxifen show promise in treatment, with the disease rarely impacting long-term survival.
Area of Science:
- Nephrology
- Urology
- Cardiovascular Medicine
Background:
- Retroperitoneal fibrosis (RPF) is a condition characterized by a fibrous mass in the retroperitoneum.
- This mass can encase the aorta and surrounding structures, frequently involving the ureters.
Observation:
- Patients may present with flank pain and acute renal failure due to ureteral obstruction.
- A strong association exists between RPF and atherosclerotic disease of the aorta.
Findings:
- The exact pathogenesis of retroperitoneal fibrosis remains unknown.
- Prednisone demonstrates efficacy in treating RPF, while tamoxifen may also be effective.
- RPF typically does not result in long-term morbidity or affect patient survival.
Implications:
- Early recognition and treatment of RPF are crucial to prevent acute kidney injury.
- Further research into the pathogenesis of RPF may reveal novel therapeutic targets.
- Understanding the link between RPF and atherosclerosis could improve patient management.